CA3243300A1 - Conjugates of tubulin peptide inhibitors useful as therapeutic agents - Google Patents
Conjugates of tubulin peptide inhibitors useful as therapeutic agentsInfo
- Publication number
- CA3243300A1 CA3243300A1 CA3243300A CA3243300A CA3243300A1 CA 3243300 A1 CA3243300 A1 CA 3243300A1 CA 3243300 A CA3243300 A CA 3243300A CA 3243300 A CA3243300 A CA 3243300A CA 3243300 A1 CA3243300 A1 CA 3243300A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- nrcrd
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280409P | 2021-11-17 | 2021-11-17 | |
| US63/280,409 | 2021-11-17 | ||
| PCT/US2022/079973 WO2023091957A1 (en) | 2021-11-17 | 2022-11-16 | Peptide conjugates of peptidic tubulin inhibitors as therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243300A1 true CA3243300A1 (en) | 2023-05-25 |
Family
ID=84799580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243300A Pending CA3243300A1 (en) | 2021-11-17 | 2022-11-16 | Conjugates of tubulin peptide inhibitors useful as therapeutic agents |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230416331A1 (enExample) |
| EP (1) | EP4433095A1 (enExample) |
| JP (1) | JP2024542212A (enExample) |
| KR (1) | KR20240130157A (enExample) |
| CN (1) | CN118574642A (enExample) |
| AU (1) | AU2022390891A1 (enExample) |
| CA (1) | CA3243300A1 (enExample) |
| CL (1) | CL2024001486A1 (enExample) |
| CO (1) | CO2024007413A2 (enExample) |
| IL (1) | IL312884A (enExample) |
| MX (1) | MX2024005938A (enExample) |
| PE (1) | PE20242180A1 (enExample) |
| TW (1) | TW202330015A (enExample) |
| WO (1) | WO2023091957A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2399267T3 (es) * | 2005-01-18 | 2013-03-27 | The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations | Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno |
| JP6262768B2 (ja) * | 2013-01-03 | 2018-01-17 | セルトリオン， インク． | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
| WO2018023098A1 (en) * | 2016-07-29 | 2018-02-01 | Memorial Sloan Kettering Cancer Center | Radiolabeled ligands for targeted pet/spect imaging and methods of their use |
| KR20220052918A (ko) * | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
| PH12022550037A1 (en) * | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
-
2022
- 2022-11-16 TW TW111143837A patent/TW202330015A/zh unknown
- 2022-11-16 WO PCT/US2022/079973 patent/WO2023091957A1/en not_active Ceased
- 2022-11-16 AU AU2022390891A patent/AU2022390891A1/en active Pending
- 2022-11-16 CN CN202280089024.1A patent/CN118574642A/zh active Pending
- 2022-11-16 IL IL312884A patent/IL312884A/en unknown
- 2022-11-16 US US18/056,117 patent/US20230416331A1/en active Pending
- 2022-11-16 KR KR1020247020055A patent/KR20240130157A/ko active Pending
- 2022-11-16 EP EP22836006.1A patent/EP4433095A1/en active Pending
- 2022-11-16 MX MX2024005938A patent/MX2024005938A/es unknown
- 2022-11-16 JP JP2024529599A patent/JP2024542212A/ja active Pending
- 2022-11-16 CA CA3243300A patent/CA3243300A1/en active Pending
- 2022-11-16 PE PE2024001102A patent/PE20242180A1/es unknown
-
2024
- 2024-05-16 CL CL2024001486A patent/CL2024001486A1/es unknown
- 2024-06-13 CO CONC2024/0007413A patent/CO2024007413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118574642A (zh) | 2024-08-30 |
| EP4433095A1 (en) | 2024-09-25 |
| KR20240130157A (ko) | 2024-08-28 |
| CL2024001486A1 (es) | 2024-11-29 |
| AU2022390891A1 (en) | 2024-06-06 |
| PE20242180A1 (es) | 2024-11-07 |
| TW202330015A (zh) | 2023-08-01 |
| US20230416331A1 (en) | 2023-12-28 |
| IL312884A (en) | 2024-07-01 |
| CO2024007413A2 (es) | 2024-11-18 |
| WO2023091957A1 (en) | 2023-05-25 |
| MX2024005938A (es) | 2024-08-14 |
| JP2024542212A (ja) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7673041B2 (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| TWI820077B (zh) | 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法 | |
| CN112625028B (zh) | 用于抑制shp2活性的化合物和组合物 | |
| JP2022541749A5 (enExample) | ||
| US12234212B2 (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| US20230416331A1 (en) | Peptide conjugates of peptidic tubulin inhibitors as therapeutics | |
| EA051761B1 (ru) | Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств | |
| WO2022155172A1 (en) | Peptide conjugates of therapeutics | |
| EA051826B1 (ru) | Пептидные конъюгаты цитотоксинов в качестве терапевтических средств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240806 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240807 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240819 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240819 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241003 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241204 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251104 |